DNA repair pathways in human multiple myeloma: Role in oncogenesis and potential targets for treatment
Open accessThe DOI matches its Crossref record; 21 of the 21 references it cites were found in a registry or an index.
Abstract
Every day, cells are faced with thousands of DNA lesions, which have to be repaired to preserve cell survival and function. DNA repair is more or less accurate and could result in genomic instability and cancer. We review here the current knowledge of the links between molecular features, treatment, and DNA repair in multiple myeloma (MM), a disease characterized by the accumulation of malignant plasma cells producing a monoclonal immunoglobulin. Genetic instability and abnormalities are two hallmarks of MM cells and aberrant DNA repair pathways are involved in disease onset, primary translocations in MM cells, and MM progression. Two major drugs currently used to treat MM, the alkylating agent Melphalan and the proteasome inhibitor Bortezomib act directly on DNA repair pathways, which are involved in response to treatment and resistance. A better knowledge of DNA repair pathways in MM could help to target them, thus improving disease treatment.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
1 retracted
Pichiorri, F., Suh, S.-S., Rocci, A., De Luca, L., Taccioli, C., Santhanam, R., Zhou, W., Benson, D. M., Hofmainster, C., Alder, H., et al. (2010) · Cancer Cell · doi:10.1016/j.ccr.2010.09.005 · Cited by 436
RetractedThe DNA Damage Response: Making It Safe to Play with Knives
Ciccia, A., & Elledge, S. J. (2010) · Molecular Cell · doi:10.1016/j.molcel.2010.09.019 · Cited by 4,368 · cited 9×
“69 In contrast, histone H4 acetylation by Tip60 blocks 53BP1 recruitment and promotes BRCA1 occupancy and, subsequently, HR.71 HR is also promoted by PARP1 and by proteins implicated in the inherited disorder, Fanconi anemia, from the toxic interference of NHEJ proteins.72-74 Cell cycle-regulated proteins such as cycl…”
BackgroundInfluentialThe mechanism of double-strand DNA break repair by the nonhomologous DNA end-joining pathway
Lieber, M. R. (2010) · Annual Review of Biochemistry · doi:10.1146/annurev.biochem.052308.093131 · Cited by 2,882 · cited 2×
“Resolution of double-strand DNA breaks during CSR requires DNA repair pathways, including non-homologous end joining (NHEJ) (discussed below).(3,5,14,18) Double-strand DNA breaks can also occur during SHM, to generate deletions and insertions in IGV genes, which surprisingly occur in general as multiples of nucleotide…”
BackgroundHoeijmakers, J. H. J. (2009) · New England Journal of Medicine · doi:10.1056/nejmra0804615 · Cited by 2,239 · cited 1×
“About 10(5) DNA hits can occur on a daily basis in a cell, caused by spontaneous decay (depurination, deamination, and methylation reactions), replication errors, cellular metabolism, reactive oxygen species, and by environmental DNA damaging agents such as UV light, ionizing radiation, or chemicals.(55,56) It is not…”
BackgroundIdentification of a Primary Target of Thalidomide Teratogenicity
Ito, T., Ando, H., Suzuki, T., Ogura, T., Hotta, K., Imamura, Y., Yamaguchi, Y., & Handa, H. (2010) · Science · doi:10.1126/science.1177319 · Cited by 2,136
γH2AX: a sensitive molecular marker of DNA damage and repair
Mah, L.-J., El-Osta, A., & Karagiannis, T. C. (2010) · Leukemia · doi:10.1038/leu.2010.6 · Cited by 1,557
A Long-Term Study of Prognosis in Monoclonal Gammopathy of Undetermined Significance
Kyle, R. A., Therneau, T. M., Rajkumar, S. V., Offord, J. R., Larson, D. R., Plevak, M. F., & Melton, L. J. (2002) · New England Journal of Medicine · doi:10.1056/nejmoa01133202 · Cited by 1,475
Prevalence of monoclonal gammopathy of undetermined significance
Kyle, R. A., Therneau, T. M., Rajkumar, S. V., Larson, D. R., Plevak, M. F., Offord, J. R., Dispenzieri, A., Katzmann, J. A., & Melton, L. J. (2006) · New England Journal of Medicine · doi:10.1056/nejmoa054494 · Cited by 1,423 · cited 1×
“Seminal observations have established that it is preceded by monoclonal gammopathy of undetermined significance (MGUS), a premalignant phase(2-6) that occurs in 3% of individuals over 50 years of age.(7) MGUS can persist before developing to MM at a 1% rate/year, independently of the duration of the MGUS phase.”
BackgroundLandgren, O., Kyle, R. A., Pfeiffer, R. M., Katzmann, J. A., Caporaso, N. E., Hayes, R. B., Dispenzieri, A., Kumar, S., Clark, R. J., Baris, D., et al. (2009) · Blood · doi:10.1182/blood-2008-12-194241 · Cited by 1,127 · cited 2×
“Resolution of double-strand DNA breaks during CSR requires DNA repair pathways, including non-homologous end joining (NHEJ) (discussed below).(3,5,14,18) Double-strand DNA breaks can also occur during SHM, to generate deletions and insertions in IGV genes, which surprisingly occur in general as multiples of nucleotide…”
BackgroundPromiscuous Mutations Activate the Noncanonical NF-κB Pathway in Multiple Myeloma
Keats, J. J., Fonseca, R., Chesi, M., Schop, R., Baker, A., Chng, W.-J., Van Wier, S., Tiedemann, R., Shi, C.-X., Sebag, M., et al. (2007) · Cancer Cell · doi:10.1016/j.ccr.2007.07.003 · Cited by 983 · cited 1×
“Constitutive NFκB activity is observed in primary MMCs from about 20% of newly diagnosed patients,(35-38) in part due to alterations of various genes coding for proteins of the NFκB pathway.(36,37,39) Both canonical and non-canonical NFκB pathways are activated in MM,(40) in association with drug resistance and/or wit…”
Background
Cited by
Lun, X., Wells, J. C., Grinshtein, N., King, J. C., Hao, X., Dang, N.-H., Wang, X., Aman, A., Uehling, D., Datti, A., et al. (2016) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-15-1798 · Cited by 197
“Moreover, we believe that our observations are not limited to repurposing DSF solely for glioma but could be used when combined with a copper supplement in a number of cancers for which resistance to DNA-damaging agents is commonly observed and in situations when targeting DNA repair coupled with proteasome inhibition…”
BackgroundDrug resistance in multiple myeloma: Soldiers and weapons in the bone marrow niche
Solimando, A. G., Malerba, E., Leone, P., Prete, M., Terragna, C., Cavo, M., & Racanelli, V. (2022) · Frontiers in Oncology · doi:10.3389/fonc.2022.973836 · Cited by 65
“The former includes genetic and epigenetic alterations, as occurs in other solid and hematological malignancies (10–14), the overexpression of drug efflux pumps (15), alteration of drug targets (16), and a dysregulation of intracellular signaling pathways, such as those that mediate apoptosis (17), autophagy, and DNA…”
BackgroundHMGB1 knockdown increases MM cell vulnerability by regulating autophagy and DNA damage repair
Guo, X., He, D., Zhang, E., Chen, J., Chen, Q., Li, Y., Yang, L., Yang, Y., Zhao, Y., Wang, G., et al. (2018) · Journal of Experimental & Clinical Cancer Research · doi:10.1186/s13046-018-0883-3 · Cited by 36
Deacetylation induced nuclear condensation of HP1γ promotes multiple myeloma drug resistance
Li, X., Wang, S., Xie, Y., Jiang, H., Guo, J., Wang, Y., Peng, Z., Hu, M., Wang, M., Wang, J., et al. (2023) · Nature Communications · doi:10.1038/s41467-023-37013-x · Cited by 27
Metadata
- Authors
- Gourzones-Dmitriev, C., Kassambara, A., Sahota, S., Rème, T., Moreaux, J., Bourquard, P., Hose, D., Pasero, P., Constantinou, A., & Klein, B.
- Venue
- Cell Cycle
- Publisher
- Informa UK Limited
- Published
- 2013-09
- Volume
- 12
- Issue
- 17
- Pages
- 2760-2773
- ISSN
- 1538-4101 (ISSN-L)
- 1551-4005
- OpenAlex
- W2055453653
- Cited by
- 61
- References
- 21
- FWCI
- 2.77
- Type
- journal article
- Language
- en
- Open access
- bronze
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: DNA repair pathways in human multiple myeloma: Role in oncogenesis and potential targets for treatment. https://app.cochat.ai/papers/10.4161/cc.25951
- The paper
- Gourzones-Dmitriev, C., Kassambara, A., Sahota, S., Rème, T., Moreaux, J., Bourquard, P., Hose, D., Pasero, P., Constantinou, A., & Klein, B. (2013). DNA repair pathways in human multiple myeloma: Role in oncogenesis and potential targets for treatment. Cell Cycle. https://doi.org/10.4161/cc.25951
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.